Pharmacotherapy of type 1 diabetes - part 1: yesterday.

IF 2.7 3区 医学 Q3 PHARMACOLOGY & PHARMACY Expert Opinion on Pharmacotherapy Pub Date : 2025-02-01 Epub Date: 2025-01-28 DOI:10.1080/14656566.2025.2454280
Marc Rendell
{"title":"Pharmacotherapy of type 1 diabetes - part 1: yesterday.","authors":"Marc Rendell","doi":"10.1080/14656566.2025.2454280","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes is a unique autoimmune attack on the β cell of the pancreatic islet resulting in progressive destruction of these cells and as a result the ability of the body to maintain insulin production. The consequences of insulin deficiency are very severe, and the disease was fatal prior to the ability to extract insulin from animal pancreas in 1921. We review progress in the treatment of childhood type 1 diabetes over the past 100 years.</p><p><strong>Areas covered: </strong>We used PubMed and standard search engines to search for the evolution of diagnosis and treatment of type 1 diabetes.</p><p><strong>Expert opinion: </strong>Insulin replacement proved lifesaving for children afflicted with type 1 diabetes. However, it was observed that these children suffered from microvascular and large vessel disease. The Diabetes Control and Complications Trial (DCCT) with its extension Epidemiology of Diabetes Interventions and Complications Trial (EDIC) proved that control of blood glucose as close to normal as possible could prevent these diabetes-related conditions. Many formuations of insulin with varying onset and duration of action have been developed; yet normalization of glucose levels is difficult due to hypoglycemic events. There is continued progress toward that goal.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"313-324"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2025.2454280","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Type 1 diabetes is a unique autoimmune attack on the β cell of the pancreatic islet resulting in progressive destruction of these cells and as a result the ability of the body to maintain insulin production. The consequences of insulin deficiency are very severe, and the disease was fatal prior to the ability to extract insulin from animal pancreas in 1921. We review progress in the treatment of childhood type 1 diabetes over the past 100 years.

Areas covered: We used PubMed and standard search engines to search for the evolution of diagnosis and treatment of type 1 diabetes.

Expert opinion: Insulin replacement proved lifesaving for children afflicted with type 1 diabetes. However, it was observed that these children suffered from microvascular and large vessel disease. The Diabetes Control and Complications Trial (DCCT) with its extension Epidemiology of Diabetes Interventions and Complications Trial (EDIC) proved that control of blood glucose as close to normal as possible could prevent these diabetes-related conditions. Many formuations of insulin with varying onset and duration of action have been developed; yet normalization of glucose levels is difficult due to hypoglycemic events. There is continued progress toward that goal.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1型糖尿病的药物治疗-第一部分:昨天。
1型糖尿病是一种独特的自身免疫攻击胰岛的β细胞,导致这些细胞的进行性破坏,从而导致身体维持胰岛素生产的能力。胰岛素缺乏的后果非常严重,在1921年能够从动物胰腺中提取胰岛素之前,这种疾病是致命的。我们回顾了过去100年来儿童1型糖尿病治疗的进展。涉及领域:我们使用PubMed和标准搜索引擎搜索1型糖尿病的诊断和治疗进展。专家意见:胰岛素替代被证明可以挽救1型糖尿病患儿的生命。然而,观察到这些儿童患有微血管和大血管疾病。糖尿病控制和并发症试验(DCCT)及其扩展的糖尿病干预和并发症流行病学试验(EDIC)证明,尽可能控制血糖接近正常水平可以预防这些糖尿病相关疾病。已经开发了许多具有不同起效和作用持续时间的胰岛素制剂;然而,由于低血糖事件,使血糖水平正常化是困难的。朝着这一目标不断取得进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
期刊最新文献
Emerging approaches to difficult-to-manage axial spondyloarthritis. Phenotypic response surface-guided pharmacotherapy for personalized combination treatment in complex diseases. New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin. New perspectives in managing chronic pelvic pain in endometriosis: the role of GnRH antagonists versus dienogest. Optimizing the use of novel systemic therapies in atopic dermatitis: an insight into therapeutic transitions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1